Robert Landewé

Professor

Amsterdam University Medical Centers

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Robert Landewé is a faculty member at the Amsterdam University Medical Center in the Netherlands. His research primarily focuses on axial spondyloarthritis, including the evaluation of clinical trials, structural damage quantification, and the impact of biologics on related conditions. He has contributed to several recent publications regarding the assessment of peripheral arthritis, long-term monitoring of immunomodulatory drugs, and radiological phenotypes in spondyloarthritis.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Helena Marzo-Ortega

University of Leeds

UNITED KINGDOM

Robert Landewé

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Correspondence on ‘Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring’ by Protopopov et al.

ASAS recommendations on reporting axial spondyloarthritis clinical trials

Long-Term Routine Laboratory Toxicity Monitoring of Immunomodulatory Drugs in Rheumatoid Arthritis

Evaluation of instruments assessing peripheral arthritis in spondyloarthritis: an analysis of the ASAS-PerSpA study

Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study

Sacroiliac damage on MRI in axial spondyloarthritis and chronic back pain, women with postpartum back pain, runners and healthy subjects

Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA study

Radiological phenotypes in pulmonary sarcoidosis: a reliability study of newly defined high-resolution computer tomography phenotypes

Comparing the construct validity of measurement instruments for pain and stiffness in patients with axial spondyloartwhritis: cross-sectional analysis in the OASIS cohort

ASAS consensus definition of early axial spondyloarthritis

Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM

Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?

Controversies in rheumatology: telemedicine—friend or foe?

Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry

Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Gladman

Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physicianreported spondylitis’?’ by Siebert and Marzo-Ortega

Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Klopfensteinet al

Instrument selection for the ASAS core outcome set for axial spondyloarthritis

Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanoset al

Collaborators (17)

Helena Marzo-Ortega

SFE van Weely

Sofia Ramiro

Tom Huizinga

Carter Thorne

Patrick Verschueren

christopher ritchlin

Denis Poddubnyy

Walter P Maksymowych

Floris van Gaalen

KAREN SALOMON-ESCOTO

Mikkel Østergaard

Désirée van der Heijde

Margaret J Larché

Christian Dejaco

Juergen Braun

Raj Sengupta

Make your next move.